Background: There is a lack of knowledge in full‐body skin examinations (FBSEs) in the context of pathogenic or likely pathogenic variants (PV/LPV) in skin cancer predisposition genes (CPGs). This study assessed the association between carrier status of PV/LPV in skin CPGs and FBSEs and described the patterns of family letter receipt, familial disclosure, and cascade testing among high‐risk individuals. Methods: Between July and September 2023, we surveyed participants enrolled in the Chicago Cancer Prone Study. Carrier status of PV/LPV in skin CPGs was defined as having been told by a genetic counselor that they have a PV/LPV in CDKN2A , TP53 , PTEN , BRIP1 , PALB2 , ATM , and/or CHEK2 genes. FBSEs were assessed by asking individuals whether they ever had an FBSE and modeled using logistic regression. Results: Of 579 individuals (mean age, 59.5 years), 11.6% carry PV/LPV in skin CPGs and 63.8% ever had a FBSE. Carriers had greater odds of FBSEs than non‐carriers (adjusted odds ratio, 2.15; 95% CI, 1.03–4.52). White race, older age, and female sex were associated with increased odds of FBSEs. Among carriers, 65.3% received a family letter from their genetic counselor after testing; 91.0% disclosed their PV/LPV‐carrying status to any family members, and 62.7% of the individuals' family members underwent genetic testing. Conclusions: We found greater odds of FBSEs among PV/LPV carriers, notable disparities in FBSEs, and prevalent family letter receipt, familial disclosure, and cascade testing. This study highlights the role of PV/LPV‐carrying status on FBSEs and the potential need for comprehensive guidelines beyond known risk factors to optimize skin cancer screening in high‐risk populations.